Contineum Therapeutics Welcomes New Board Member Diego Miralles Contineum Therapeutics has announced the addition of Diego Miralles, M.D., to its board of directors. Dr. Miralles commended the company's innovative pipeline, including clinical trials for PIPE-791 and PIPE-307, which target idiopathic pulmonary fibrosis and multiple sclerosis. This move aligns with Contineum's focus on advancing novel oral therapies for unmet medical needs.1